H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Epizyme (EPZM) today and set a price target of $36.00. The company’s shares closed last Thursday at $6.81, close to its 52-week low of $6.70.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 13.9% and a 48.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
Currently, the analyst consensus on Epizyme is a Strong Buy with an average price target of $19.00, a 153.3% upside from current levels. In a report issued on April 23, Cowen & Co. also initiated coverage with a Buy rating on the stock with a $14.00 price target.
See today’s analyst top recommended stocks >>
Based on Epizyme’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.38 million and GAAP net loss of $66.23 million. In comparison, last year the company earned revenue of $4.29 million and had a GAAP net loss of $56.4 million.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPZM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
